As the mTOR pathway is activated in colorectal cells with high MAGEA3 levels, rapamycin may have the potential therapeutic efficacy as an indirect targeting approach against MAGEA3-high CRC. The gene discussed is MAGEA3; the disease is colorectal carcinoma.